A novel mechanism of plasmin-induced mitogenesis in fibroblasts

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 1, 2005, Pages 163-169

  Mandal, S K ^a   Rao, L V M ^a   Tran, T T T ^a   Pendurthi, U R ^a,b  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b Biomedical Research   (United States)

Author keywords

Cell proliferation; Cyr61; Plasmin; Protease activated receptors

Indexed keywords

ANTIBODY; CYR ANTIBODY; CYSTEINE RICH PROTEIN 61; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMIN; PROTEINASE ACTIVATED RECEPTOR 1; UNCLASSIFIED DRUG; CYR61 PROTEIN, HUMAN; CYR61 PROTEIN, MOUSE; DNA; IMMEDIATE EARLY PROTEIN; MITOGENIC AGENT; PROTEINASE ACTIVATED RECEPTOR; SIGNAL PEPTIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; FIBROSIS; METABOLISM; TIME; WOUND HEALING;

ANIMALS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; FIBROSIS; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOBLOTTING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGENS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMIN; RECEPTORS, PROTEINASE-ACTIVATED; TIME FACTORS; WOUND HEALING;

EID: 20444497340     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.01054.x     Document Type: Article

References (36)

1. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998; 91: 255-85.
2. Pepper MS. Role of the matrix metalloproteinases and plasminogen activator-plasmin system in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-17.
3. Lijnen HR. Plasmin and matrix metalloproteinases. Thromb Haemost 2001; 86: 324-33.
4. Ploplis VA, Castellino FJ. Gene targeting of components of the fibrinolytic system. Thromb Haemost 2002; 87: 22-31.
5. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110: 1361-7.
6. Yee JA, Yan L, Dominguez JC, Allan EH, Martin TJ. Plasminogen-dependent activation of latent transforming growth factor beta by growing cultures of osteoblast-like cells. J Cell Physiol 1993; 157: 528-34.
7. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC. Release and activation of platelet latent TGF-B in blood clots during dissolution with plasmin. Nat Med 1995; 1: 932-7.
8. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990; 110: 767-75.
9. George SJ, Johnson JL, Smith MA, Jackson CL. Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenvous vein. Vascular Res 2001; 38: 492-51.
10. Kirchheimer JC, Wojta J, Christ G, Binder BR. Proliferation of human epidermal tumor cell line stimulated by urokinase. FASEB J 1987; 1: 125-8.
11. Baron-Van Evercooren A, Leprince P, Rogister B, Lefebvre PP, Delree P, Selak I, Moonen G. Plasminogen activators in developing peripheral nervous system, cellular origin and mitogenic effect. Brain Res 1987; 433: 101-8.
12. Kirchheimer JC, Wojta J, Hienert G, Christ G, Heger ME, Pfluger H, Binder BR. Effect of urokinase on the proliferation of primary cultures of human prostatic cells. Thromb Res 1987; 48: 291-8.
13. Binder BR. Influence of urokinase on cell proliferation and invasion. Blood Coag Fibrinol 1990; 1: 717-20.
14. Herbert JM, Lamarche I, Prabonnaud V, Dol F, Gauthier T. Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem 1994; 269: 3076-80.
15. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 1998; 16: 513-28.
16. Akao M, Hasebe Y, Okumura N, Hagiwara H, Seki T, Ariga T. Plasminogen activator-plasmin system potentiates the proliferation of hepatocytes in primary culture. Thromb Res 2002; 107: 169-74.
17. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-8.
18. Pendurthi UR, Ngyuen M, Andrade-Gordon P, Petersen LC, Rao LVM. Plasmin induces Cyr61 gene expression in fibroblasts via protease activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway. Arterioscler Thromb Vasc Biol 2002; 22: 1421-6.
19. Lau LF, Lam S. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999; 248: 44-57.
20. Chen C-C, Mo F-E, Lau LF. The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts. J Biol Chem 2001; 276: 47329-34.
21. Kireeva ML, Mo F-E, Yang GP, Lau LF. Cyr61, a product of growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996; 16: 1326-34.
22. Kolesnikova T, Lau LF. Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells. Oncogene 1998; 16: 747-54.
23. Grzeszkiewicz TM, Kirschling DJ, Chen N, Lau LF. CYR61 stimulates skin fibroblast migration through integrin αvβ5 and enhances mitogenesis through integrin αvβ3, independent of its carboxyl-terminal domain. J Biol Chem 2001; 276: 21943-50.
24. O'Brien TP, Yang GP, Sanders L, Lau LF. Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 1990; 10: 3569-77.
25. Pendurthi UR, Allen KE, Ezban M, Rao LVM. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VII: tissue factor-induced signal transduction. J Biol Chem 2000; 275: 14632-41.
26. Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous. Biochem 1996; 35: 266-72.
27. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003; 1: 1495-503.
28. Kireeva ML, Latinkic BV, Kolesnikova TV, Chen CC, Yang GP, Abler AS, Lau LF. Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp Cell Res 1997; 233: 63-77.
29. Kimura M, Andersen TT, Fenton IIW, Bahou W, Aviv A. Plasmin-platelet interaction involves cleavage of functional thrombin receptor. Am J Physiol 1996; 271: C54-C60.
30. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochem 1999; 38: 4572-85.
31. Loew D, Perrault C, Morales M, Moog S, Ravanat C, Schuhler S, Arcone R, Pietropaolo C, Cazenave JP, van Dorsselaer A, Lanza F. Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry. Biochem 2000; 39: 10812-22.
32. Parry MA, Myles T, Stone SR, Tschopp J. Cleavage of the thrombin receptor: identification of potential activators and inactivators. Biochem J 1996; 320: 335-41.
33. Schafer AI, Mass AK, Ware JA, Jhonson PC, Rittenhouse SE, Salzman EW. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 1986; 78: 73-9.
34. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
35. Renckens R, Weijer S, de Vos AF, Pater JM, Meijers JC, Hack CE, Levi M, van der Poll T. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol 2004; 24: 483-8.
36. Taguchi O, Gabazza EC, Yoshida M, Yamakami T, Kobayashi H, Shima T. High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clinica Chimica Acta 1996; 244: 69-81.